At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
In Brief
A Phase 1 clinical trial evaluating Biopsy Procedure, Birinapant, and 4 other interventions for Locally Recurrent Head and Neck Squamous Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 13 participants across 33 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of birinapant when given together with intensity modulated re-irradiation therapy (IMRRT) in treating patients with head and neck squamous cell carcinoma that has come back at or near the same place as the original (primary) tumor (locally recurrent). Birinapant may stop the growth of tumor cells by blocking inhibitor of apoptosis (IAP), a protein needed for tumor cell survival. IMRRT uses thin beams of radiation of different intensities that are aimed at the tumor from many angles. This type of re-irradiation therapy reduces the damage to healthy tissue near the tumor. Giving birinapant with IMRRT may lower the chance of head and neck squamous cell carcinoma growing or spreading.
Study Details
Timeline
Interventions
Undergo biopsy
Given IV
Undergo CT scan
Undergo IMRRT
Undergo MRI
Undergo PET scan